50+ Chinese IVD companies reported Q3 earnings

As of 31 October 2023, over 50 Chinese IVD listed companies have announced their Q3 financial results. 

According to the published data, the first three quarters of the total revenue of the top 10 companies are: 

Dian Diagnostics (revenue of CNY 10.292 billion yuan), Runda Medical (revenue of CNY 6.890 billion yuan), KingMed Diagnostics (revenue of CNY 6.310 billion yuan), Autobio (revenue of CNY 3.242 billion yuan), BGI Genomics (revenue of CNY 3.143 billion yuan), Sinocare (revenue of CNY 3.035 billion yuan), Snibe (revenue of CNY 2.908 billion yuan), MGI (revenue of CNY 2.204 billion yuan), Maccura (revenue of CNY 2.115 billion yuan), and Wondfo (revenue of CNY 2.004 billion yuan). 

Table 1 The total operating income and profit for the third quarters and the first three quarters

From the overall Q3 earnings data, only 11 companies (22%) had growth in total revenue in the first three quarters compared to the same period last year, as follows: 
 
Bohui Innovation Biotechnology had total revenue of CNY 806 million yuan, up 34.93% year-on-year; Dirui had total revenue of CNY 1.049 billion yuan, up 30.69% year-on-year; Snibe had total revenue of CNY 2.908 billion yuan, up 26.62% year-on-year; Succeeder’s total revenue of CNY 204 million yuan, an increase of 24.37% year-on-year; Lifotronic’s total revenue of CNY 809 million yuan, an increase of 20.15% year-on-year; Amoy Diagnostics’s total revenue of CNY 708 million yuan, an increase of 18.08% year-on-year; HOB Biotech Group’s total revenue of CNY 300 million yuan, an increase of 17.89% year-on-year; BSBE’s total revenue of CNY 1,234 million yuan, an increase of 9.93% year-on-year; Sinocare’s total revenue of CNY 3.035 billion yuan, an increase of 6.46% year-on-year, and total revenue of CNY 151 million yuan for AVE Science & Technology, an increase of 0.19% year-on-year.
 
The revenue of IVD-related listed companies in the first three quarters are as follows:  
Mindray’s revenue was 27.3 billion yuan, with net profit of 9.83 billion yuan attributable to its parent company, Wantai Biopharm’s revenue was 4.97 billion yuan, with net profit of 1.81 billion yuan, Zhongyuan Union Stem Cell Bioengineering’s revenue was 1.2 billion yuan, with net profit of 133 million yuan, Livzon Pharm’s revenue was 9.66 billion yuan, with net profit of 1.6 billion yuan, Edan Instruments’s revenue was 2.34 billion yuan, with net profit of 339 million yuan, Skyray Instrument’s revenue was 616 million yuan, with net profit of -14 million yuan.